Allos Therapeutics to Present at Four Upcoming Investor Conferences
June 04 2010 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present at the following
four investor conferences during the month of June.
June 9, 2010BofA Merrill Lynch 2010 SMid Cap ConferenceThe
Intercontinental Boston Hotel, Boston1:40 p.m. ET
June 10, 2010Jefferies 2010 Global Life Sciences ConferenceThe
Grand Hyatt, New York8:30 a.m. ET
June 10, 20109th Annual Needham Healthcare ConferenceNew York
Palace Hotel, New York City2:40 p.m. ET
June 16, 2010ThinkEquity’s Mid Year Check-Up on Healthcare
ConferencePrinceton Club, New York City1:00 p.m. ET
Attendance at these conferences is by invitation only. A live
audio webcast of select presentations can be accessed from and
available for replay through a link on the home page and investor
relations section of the Allos corporate website.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is the
first and only drug approved in the U.S. for the treatment of
patients with relapsed or refractory peripheral T-cell lymphoma.
Allos is also developing FOLOTYN in other potential indications.
Allos retains exclusive worldwide rights to FOLOTYN for all
indications. Allos is headquartered in Westminster, CO. For
additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2010
and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in the presentation. All forward-looking statements are
based on information currently available to the Company on the date
thereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of these presentations, except as
required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024